A contemporary review on combination therapy for hypertension management in India
DOI:
https://doi.org/10.18203/2349-3933.ijam20261093Keywords:
Hypertension management, Single-pill combination, Low-dose combination, Indian phenotype, Resting heart rateAbstract
Hypertension affects nearly one-third of Indian adults, yet only one in six patients achieve adequate blood pressure control. This narrative, evidence-informed review synthesizes data from PubMed, Scopus and Google Scholar (2000–2025) on antihypertensive combination therapy, with additional focus on Indian epidemiology and prescribing patterns. Evidence suggests that early initiation of combination therapy—particularly as single-pill combinations (SPCs)—may offer more rapid and sustained blood pressure reduction by targeting multiple pathophysiological pathways simultaneously. Indian patients have a unique cardiometabolic phenotype characterized by increased abdominal obesity, diabetes, dyslipidemia, heightened sympathetic tone, elevated resting heart rate, and enhanced renin-angiotensin-aldosterone system (RAAS) activation, resulting in higher cardiovascular risk at younger ages. This review evaluates clinical evidence from dual, triple, and quadruple combination trials, summarizes current global and regional guideline recommendations, and highlights gaps in Indian practice, including persistent underutilization of combination regimens in moderate- to high-risk patients. The objective is to review global evidence for Indian clinical practice and discuss strategies for optimizing risk-stratified hypertension management.
References
World Health Organization. Global report on hypertension 2025: high stakes: turning evidence into action. Available at: https://www.who.int/publica tions/i/item/9789240115569. Accessed on 12 January 2026.
Burnier M. Antihypertensive Combination Treatment: State of the Art. Curr Hypertens Rep. 2015;17:51.
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122:290-300.
Bakris GL. Combined Therapy With a Calcium Channel Blocker and an Angiotensin II Type 1 Receptor Blocker. J Clin Hypertens. 2008;10:27-32.
Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82(10):e212-e316.
Azizi M, Juraschek SP. A trans-Atlantic perspective on the 2025 AHA/ACC Guidelines for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Circulation. 2025;152:743-7.
Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, et al. 2025 AHA/ACC/AANP/AAPA/ ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Hypertension. 2025;82.
McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al; ESC Scientific Document Group. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018.
Salam A, Kanukula R, Atkins E, Wang X, Islam S, Kishore SP, et al. Efficacy and safety of dual combination therapy of blood pressure-lowering drugs as initial treatment for hypertension: a systematic review and meta-analysis of randomized controlled trials. J Hypertens. 2019;37:1768-74.
Bennett A, Chow CK, Chou M, Dehbi HM, Webster R, Salam A, et al. Efficacy and Safety of Quarter-Dose Blood Pressure-Lowering Agents: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Hypertens Dallas Tex 1979. 2017;70:85-93.
Prabhakaran D, Roy A, Chandrasekaran AM, Kondal D, Mukherjee S, Kiru G, et al. Comparison of dual therapies for hypertension treatment in India: a randomized clinical trial. Nat Med. 2025;31:3169-75.
Alexander T, Hiremath JS, Swahney JPS, Chandra S, Jain P, Chandra P, et al. Identifying Drug Prescription in Newly Diagnosed Hypertension Patients in India. J Clin Hypertens Greenwich Conn. 2025;27:e14963.
Webster R, Salam A, de Silva HA, Selak V, Stepien S, Rajapakse S, et al. Fixed Low-Dose Triple Combination Antihypertensive Medication vs Usual Care for Blood Pressure Control in Patients With Mild to Moderate Hypertension in Sri Lanka: A Randomized Clinical Trial. JAMA. 2018;320:566-79.
Rodgers A, Salam A, Schutte AE, Cushman WC, de Silva HA, Di Tanna GL, et al. Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension. JACC. 2024;84:2393-403.
Rodgers A, Salam A, Schutte AE, Cushman WC, Silva HA de, Tanna GLD, et al. Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial. The Lancet. 2024;404:1536-46.
European Society of Cardiology. A single tablet with 4 blood pressure-lowering drugs can be more effective than taking 3 drugs in separate pills. Available at: https://www.escardio.org/The-ESC/ Press-Office/Press-releases/A-single-tablet-with-4-blood-pressure-lowering-drugs-can-be-more-effective-than-taking-3-drugs-in-separate-pills. Accessed on 12 January 2026.
Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R, Tandon N, Das AK, et al. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11:474-89.
Hiremath JS, Wander GS, Dasbiswas A, Mantri RR, Khan A, Bardoloi N, et al. Bridging the Gap: Managing Hypertension in Indian Patients with Metabolic Syndrome. J Assoc Physicians India. 2025;73(5):e34-e40.
Zhao G, Wang T, Luan Y, Xu Y, Qin N, Chen W, et al. Research progress on the correlation between renin-angiotensin-aldosterone system (RAAS) and cardiovascular and cerebrovascular diseases. J Renin Angiotensin Aldosterone Syst. 2025;26:14703203251351194.
Chopra HK, Nanda NC, Das AK, Kripalani A, Jadhav U, Wander GS, et al. BEAT-HTN India: Burden, Epidemiology, and Trends of Hypertension - A Nationwide Survey. Cardiol Res. 2025;16:403-12.
Ho JE, Larson MG, Ghorbani A, Cheng S, Coglianese EE, Vasan RS, et al. Long‐term Cardiovascular Risks Associated With an Elevated Heart Rate: The Framingham Heart Study. J Am Heart Assoc Cardiovasc Cerebrovasc Dis. 2014;3:e000668.
Gorostidi M, De La Sierra A. Combination Therapy in Hypertension. Adv Ther. 2013;30:320-36.
Verma N, Rastogi S, Chia Y, Siddique S, Turana Y, Cheng H, et al. Non‐pharmacological management of hypertension. J Clin Hypertens. 2021;23:1275-83.
Rosas-Peralta M, Mancia G, Camafort M, Galván-Oseguera H, Ferrario CM, Alcocer L, et al. Single pill combination therapy for hypertension: New evidence and new challenges: Combination Therapy for Hypertension. Trends Cardiovasc Med. 2025;35(8):497-503.
Downloads
Published
How to Cite
Issue
Section
